2021.06.30
On June 30, 2021, HUTCHMED (China) Limited (hereinafter referred to as “HUTCHMED”) issued approximately 104 million shares (excluding the green shoes) globally and was listed on the Main Board of the Hong Kong Stock Exchange at the offering price of HK $40.10 per share, raising total funds of more than HK $4 billion or HK $5 billion from investors (assuming the exercise of the green shoes). The share code is 0013.
After the listing, HUTCHMED became the first biopharmaceutical company to be simultaneously listed on the stock exchange in London, New York and Hong Kong. This financing marks the second large-scale listing in the healthcare industry in Hong Kong to date in 2021.
HUTCHMED is an innovative commercial-stage biopharmaceutical company committed to the discovery, global development and commercialization of targeted drug and immunotherapy for cancer and autoimmune diseases. Its team of over 1,300 professionals has advanced its 10 self-discovered cancer drug candidates to clinical studies worldwide, of which the first two innovative oncology drugs are now approved and on the market, and the third is in the process of applying for marketing approval.
As the PRC legal counsel to the joint sponsors and underwriters of this project, JunHe provided high quality, rigorous and efficient legal services, overcoming the adverse effect of the epidemic and other factors. JunHe assisted the underwriters in conducting due diligence, reviewing and revising the prospectus and the listing-related application and offering documents, and issued Chinese legal opinion. The earnest working attitude and professional service ability of JunHe won the trust and appreciation of HUTCHMED, various professional clients and the other intermediaries.
The lead partner of this project was YU, Yongqiang (YY), and the partner in charge of the internal audit was ZHOU, Fang.
